The Operation Warp Speed Contracts and FDA's Process

As part of Operation Warp Speed, the Trump administration entered into contracts with multiple drugmakers. The contracts were generally signed while potential vaccines were still in clinical trials. Experts told us this was smart because the Trump administration didn't know which vaccines from which drugmakers would work, how effective they would be or how quickly they could be produced. "That was the whole approach of Operation Warp Speed," said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security. "Not knowing which one would cross the finish line, the Trump administration took a portfolio approach and invested in multiple vaccines." Here's what the Trump team's contracts called for drugmakers to supply to the U.S. government: Pfizer-BioNTech: 100 million doses (two-dose regimen) Moderna: 100 million doses (two-dose regimen) Johnson & Johnson: 100 million doses (one-dose regimen) AstraZeneca: 300 million doses (two-dose regimen) Novavax: 100 million doses (two-dose regimen) Sanofi-GlaxoSmithKline: 100 million doses (one- or two-dose regimen)